undamentalytics Newsletter
Sign in

Aclaris Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Aclaris Therapeutics, Inc. had total assets of $160m, total liabilities of $57.4m and shareholders' equity of $103m. It held $20.0m in cash against $0 of debt: net cash of $20.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents20573422274540252019
Receivables01111000——
Inventory—10———————
Total current assets20017984572052321291269698
Goodwill1919————————
Total assets2442769871251255197220160180
Accounts payable8121051010951316
Deferred revenue (current)———————444
Total current liabilities13272215232231322928
Long-term debt—30—11——————
Total debt030—111100000
Total liabilities18602833545740655755
Shareholders' equity2252157038197198157156103125
Net debt (negative = net cash)−20−27−34−11−17−45−40−25−20−19
Shares outstanding31m—41m45m61m67m71m—120m140m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ACRS vs COYAACRS vs APLMACRS vs ADAG

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aclaris Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aclaris Therapeutics, Inc.